Novartis: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
The registry lists 34 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Novartis as lead sponsor. 3 are open to participants now and 17 have results posted.
Phase 1 12Phase 2 17Phase 3 5Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingNCT07387926Phase 1/2
- Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruitingNCT05541341
- Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 3
- Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04225676Phase 2Results posted
- Phase III B in Acute Lymphoblastic LeukemiaCompletedNCT03123939Phase 3Results posted
- Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02435849Phase 2Results posted
- A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
- Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02228096Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedNCT01930162Phase 2Results posted
- Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute LeukemiaCompletedNCT01826214Phase 2Results posted
- A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.CompletedNCT01743989Phase 3Results posted
- Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyCompletedNCT01735955Phase 4Results posted
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)TerminatedNCT01685021Phase 2Results posted
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01520922Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)CompletedNCT01077544Phase 1Results posted
- A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric LeukemiaTerminatedNCT00866281Phase 1/2Results posted
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
- An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 2Results posted
- A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
- A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia PatientsCompletedNCT07644351
- A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia PatientsCompletedNCT07039383
- Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS DataCompletedNCT06392763
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingNCT05397496Phase 1
- CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)CompletedNCT05349201
- CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic LeukemiaWithdrawnNCT05168748Phase 1
- MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaNo longer availableNCT04559555
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruitingNCT03960840Phase 1/2
- Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaWithdrawnNCT03628053Phase 3
- Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
- A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLCompletedNCT00384228Phase 1/2
- Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00154349Phase 2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1